Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 17 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-32.72 Insider Own- Shs Outstand0.26M Perf Week-21.94%
Market Cap1.85M Forward P/E- EPS next Y-9.90 Insider Trans- Shs Float- Perf Month-17.21%
Income-8.69M PEG- EPS next Q-6.30 Inst Own1.33% Short Float- Perf Quarter-39.13%
Sales0.00M P/S- EPS this Y48.31% Inst Trans- Short Ratio0.53 Perf Half Y-57.06%
Book/sh8.58 P/B0.49 EPS next Y52.17% ROA-120.05% Short Interest0.01M Perf Year-89.59%
Cash/sh10.75 P/C0.39 EPS next 5Y- ROE-146.08% 52W Range3.48 - 40.80 Perf YTD-54.10%
Dividend Est.- P/FCF- EPS past 5Y26.37% ROI-228.17% 52W High-89.71% Beta0.96
Dividend TTM- Quick Ratio3.78 Sales past 5Y0.00% Gross Margin- 52W Low20.69% ATR (14)0.62
Dividend Ex-Date- Current Ratio3.78 EPS Y/Y TTM81.04% Oper. Margin0.00% RSI (14)37.06 Volatility16.76% 10.12%
Employees8 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price22.50
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q79.29% Payout- Rel Volume5.73 Prev Close5.20
Sales Surprise- EPS Surprise91.30% Sales Q/Q- EarningsMay 15 AMC Avg Volume10.04K Price4.20
SMA20-17.68% SMA50-24.82% SMA200-58.18% Trades Volume57,531 Change-19.23%
May-17-24 08:30AM
May-15-24 10:54PM
May-13-24 07:23AM
Apr-03-24 07:00AM
07:00AM Loading…
Apr-02-24 07:00AM
Mar-27-24 04:05PM
Mar-21-24 10:53PM
Feb-07-24 07:00AM
Feb-06-24 07:00AM
Feb-01-24 09:00AM
Jan-05-24 08:31AM
Jan-04-24 04:05PM
Dec-20-23 04:05PM
09:06AM Loading…
Nov-17-23 09:06AM
Nov-16-23 01:30PM
Nov-09-23 04:05PM
Oct-26-23 09:00AM
Aug-31-23 09:00AM
Aug-10-23 04:15PM
Jun-27-23 09:00AM
Jun-13-23 04:15PM
Jun-08-23 09:00AM
May-26-23 04:00PM
May-24-23 08:00AM
May-11-23 04:05PM
May-10-23 11:46AM
Apr-21-23 12:02PM
06:00AM Loading…
Apr-20-23 06:00AM
Mar-20-23 04:30PM
Mar-16-23 01:15PM
Feb-21-23 04:05PM
Dec-05-22 08:30AM
Nov-10-22 05:20PM
Sep-06-22 09:00AM
Aug-24-22 04:05PM
Aug-15-22 04:05PM
Jun-13-22 09:00AM
May-23-22 09:00AM
May-16-22 04:05PM
Apr-25-22 04:50PM
Apr-21-22 09:00AM
Mar-28-22 08:30AM
Mar-24-22 08:30AM
Feb-10-22 07:27AM
Feb-07-22 08:58AM
Jan-13-22 08:30AM
Jan-05-22 08:30AM
Nov-22-21 05:06AM
Nov-19-21 02:17PM
Nov-17-21 08:00AM
Nov-15-21 04:01PM
Nov-12-21 08:00AM
Nov-11-21 06:00AM
Oct-19-21 07:00AM
Dermata Therapeutics, Inc. is a clinical-stage medical dermatology company that focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin diseases. Its product pipeline includes DMT310, DMT400, and DMT410. The company was founded by David F. Hale and Gerald T. Proehl on December 8, 2014 and is headquartered in San Diego, CA.